Sellas Stock 346% Year Near Final REGAL Deaths Ahead
Sellas Life Sciences has surged 346% over the past year as its REGAL trial for a WT1-targeting cancer vaccine moves t...
This intro compares merchant acceptance for BTC and ETH, outlining where each is more commonly accepted by merchants.
27,224 articlesSellas Life Sciences has surged 346% over the past year as its REGAL trial for a WT1-targeting cancer vaccine moves t...
UPS stock in 2026 looks like a pendulum: moments of strength followed by pullbacks, driven by mixed earnings signals ...
A smaller biotech is stealing headlines in 2026 by delivering strong trial results and strategic collaborations. This...
A top tech stock faces a likely pullback in the second half of 2026 as demand shifts and costs rise. Traders should h...
Two Harbors moved its special meeting to July 2 to push the CrossCountry Mortgage deal through, while a rival bid fro...
Two funds that both orbit Bitcoin have diverged sharply in 2026: WGMI, a mining-equities play, has surged, while IBIT...
NVIDIA stock hasn't been this affordable in years, but cheap price tags don't guarantee gains. This guide breaks down...
At midyear 2026, JPMorgan’s top three overweight picks show a split: one stock has cleared its upside target, while t...
Nike has fallen 32% from its pandemic peak, boosting its dividend yield. This article weighs the dividend health, gro...
A market dip can feel like a fork in the road. This article uses history and concrete steps to show whether you shoul...
Lilly stock has faced pressure, but one key driver could keep it in buy territory. This article unpacks the core reas...
Palantir sits at the intersection of AI hype and durable analytics. This guide unpacks does palantir's valuation make...